Sep 05, 2020
The combination of LMWH (Low-Molecular-Weight Heparin) and Aspirin as a prophylaxis treatment for pre-eclampsia and SGA (Small-for-Gestational Age) neonates in medium- and high-risk women: protocol for a Systematic Review and Meta-Analysis.
- Christos-Georgios Kontovazainitis1,
- Georgios Mitsiakos2,
- Dimitra Gialamprinou2
- 1Medical School, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece;
- 22nd Neonatal Department and Neonatal Intensive Care Unit (NICU), Aristotle University of Thessaloniki, Papageorgiou Hospital, Ring Road Nea Efkarpia, 56403, Thessaloniki, Greece
Document Citation: Christos-Georgios Kontovazainitis, Georgios Mitsiakos, Dimitra Gialamprinou 2020. The combination of LMWH (Low-Molecular-Weight Heparin) and Aspirin as a prophylaxis treatment for pre-eclampsia and SGA (Small-for-Gestational Age) neonates in medium- and high-risk women: protocol for a Systematic Review and Meta-Analysis.. protocols.io https://dx.doi.org/10.17504/protocols.io.bhdtj26n
License: This is an open access document distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Created: June 10, 2020
Last Modified: September 05, 2020
Document Integer ID: 38035
The combination of LMWH (Low Molecular Weight Heparin) and Aspirin as a prophylaxis treatment for preeclampsia and SGA (Small for Gestational Age) neonates in medium and high risk women. Protocol for a Systematic Review and Meta-Analysis VERSION 2.0.pdf DOWLOAD THE ATTACHED FILE (PDF) TO VIEW THE COMPLETE PROTOCOL.
Citation: Christos - Georgios Kontovazainitis, Georgios Mitsiakos, Dimitra Gialamprinou. The combination of LMWH (Low-Molecular-Weight Heparin) and Aspirin as a prophylaxis treatment for pre-eclampsia and SGA (Small-for-Gestational Age) neonates in medium- and high-risk women: protocol for a Systematic Review and Meta-Analysis.
Registration: Our protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO).
PROSPERO Registration number: CRD42020148500
This protocol is drafted based on the updated Preferred Reporting Items in Systematic Reviews and Meta Analyses (PRISMA) guidelines(1).
Keywords: pregnancy; high-risk pregnancy; pre-eclampsia; preeclampsia; aspirin; acetylsalicylic acid; 2-acetoxybenzoic acid; heparin; low-molecular-weight heparin; LMWH; intrauterine growth restriction; IUGR; fetal growth restriction; small for gestational age; SGA; neonates; adverse events; perinatal mortality; systematic review; meta-analysis
Authors:Dr. Georgios Mitsiakos (GM), MD, PhD1
Dr. Christos-Georgios Kontovazainitis (C-GK), MSC2
Dr. Dimitra Gialamprinou (DG)1
Affiliations:
12nd Neonatal Department and Neonatal Intensive Care Unit (NICU), Aristotle University of Thessaloniki, Papageorgiou Hospital, Ring Road Nea Efkarpia, 56403, Thessaloniki, Greece
2Medical School, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece
Dr. Christos-Georgios Kontovazainitis, MSC: ckontova@auth.gr
Dr. Dimitra Gialamprinou: dgialamp@auth.gr
Corresponding author:Dr. Christos-Georgios Kontovazainitis
2nd Neonatal Department and Neonatal Intensive Care Unit
Aristotle University of Thessaloniki
Papageorgiou Hospital, Ring Road Nea Efkarpia
56403, Thessaloniki, Greece
Tel: 0030 694 538 3092
Email: ckontova@auth.gr
Author contributions: C-GK, GM and DG drafted the manuscript. C-GK, GM and DG contributed to the development of the selection criteria, the risk of bias assessment strategy and data extraction criteria. C-GK developed the search strategy. GM provided expertise on neonatology field. C-GK provided expertise on the field of obstetrics-gynaecology. All authors read, provided feedback and approved the final manuscript.
Amendments: In the event of amendments in the protocol, the date of each amendment will be accompanied by an explanation of the alterations and the relevant rationale.
Version 1.0 12.02.2020
Version 2.0 10.06.2020
·Changes in the inclusion criteria: studies that only include the secondary outcomes and not the primary ones will not be excluded. Case-control studies will be excluded.
·Changes concerning the tools used for the assessment of the risk of bias.
·Appendix 4 added.
Financial support, funding sources: The authors declare no source of institutional or external financial support in relation to this work.